Zobrazeno 91 - 100
of 1 548
pro vyhledávání: ''
Publikováno v:
Cancer Research. 81:2361-2361
Background: Patients with BRAF-mutated colorectal cancer (CRC) have a poor prognosis despite recent therapeutic advances such as combination therapy with BRAF, MEK, and EGFR inhibitors. Aim: Our aim was to clarify the functions of the microRNAs (miRN
Autor:
Ah-Rong Nam, Jeesun Yoon, Ju-Hee Bang, Tae Yong Kim, Jae-Min Kim, Do-Youn Oh, Hye-Rim Seo, Kyoung-Seok Oh
Publikováno v:
Cancer Research. 81:1079-1079
Background: DNA damage response (DDR) pathway is essential for maintaining genomic stability, cell survival, and tumorigenesis. However, the roles of DDR pathway in HER2-positive tumors remain unclear. This study aims to discover the function of DDR
Autor:
Rafael Renatino Canevarolo, Constantine N. Logothetis, Christopher L. Cubitt, Mark B. Meads, Amit A. Kulkarni, Maria D Coelho Siqueira Silva, Yosef Landesman, Oliver A. Hampton, Christopher J. Walker, Praneeth Reddy Sudalagunta, Raghunandan Reddy Alugubelli, Gabriel DeAvila, Qi Zhang, Kenneth H. Shain, Ariosto S. Silva
Publikováno v:
Cancer Research. 81:1061-1061
Introduction. Multiple myeloma (MM) is an all but incurable plasma cell malignancy without predictive biomarkers for approved therapies. Selinexor (SELI), a nuclear export inhibitor targeting exportin 1 (XPO1), is approved with dexamethasone (DEX) wi
Publikováno v:
Cancer Research. 81:1323-1323
In this study, we develop a novel autophagy inhibitor targeting one of the most aggressive cell populations present in pancreatic tumors, the pancreatic cancer stem cell (CSC). Targeting this population which has the malignant properties of tumorigen
Autor:
Ulivi Paola, Laura Matteucci, Milena Urbini, Alessandro Passardi, Gianluca Tedaldi, Giorgia Marisi, Matteo Canale, Giovanni Martinelli, Giovanni Luca Frassineti, Chiara Molinari
Publikováno v:
Cancer Research. 81:541-541
The use of liquid biopsy in the clinical management of colorectal cancer (CRC) patients is not yet a routine clinical practice, although it could give important information for tumor baseline characterization and for monitoring during treatment. In t
Autor:
Helmout Modjtahedi, Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, Said Abdullah Khelwatty
Publikováno v:
Cancer Research. 81:350-350
Background: Overexpression of the EGFR is common in patients with a wide range of cancers and the EGFR is an important target for therapy with monoclonal antibodies (mAbs) based drugs. Of these, cetuximab and panitumumab have been approved for the tr
Autor:
Michele De Palma, Alan Guichard, Chiara Cianciaruso, Martina Schmittnaegel, Amaia Martinez-Usatorre, Ece Kadioglu, Sina Nassiri, Ioanna Keklikoglou, Bruno Torchia, Etienne Meylan, Carola Ries
Publikováno v:
Cancer Research. 81:75-75
Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non-small cell lung cancer (NSCLC), often in combination with chemotherapy. However, only a minority of the patients respond and sustained remission
Autor:
Trason Thode, Mohan R. Kaadige, Sunil Sharma, Alexis Weston, Kevin Drenner, Samuel Sampson, Raffaella Soldi, Serina Ng
Publikováno v:
Cancer Research. 81:1175-1175
Introduction: Ewing's Sarcoma (ES) is a rare and aggressive pediatric bone tumor that is driven by a chromosomal translocation and fusion between EWS and FLI1 genes resulting in a chimeric protein. Nearly 85% of ES cases express the EWS/FLI protein w
Autor:
Caitlin Molczyk, Dipakkumar R. Prajapati, Michelle L. Varney, Sugandha Saxena, Rakesh K. Singh, Paran Goel
Publikováno v:
Cancer Research. 81:1087-1087
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rates of cancers, with a five-year relative survival of 9%. The significant factor contributing to low survivorship is the intrinsic resistance to chemotherapy. In the present stu
Autor:
Roxanne Diaz, Thangavel Saravanan, Saud Azam, Tariq Masoodi, Sandeep Kumar Parvathareddy, Khawla S. Al-Kuraya, Poyil Pratheeshkumar, Rafia Begum, Khadija A.S. Al-Obaisi, Sasidharan Padmaja Divya, Sarah Siraj, Zeeshan Qadri, Abdul K. Siraj
Publikováno v:
Cancer Research. 81:3192-3192
Background: PD-L1 inhibition is a promising therapeutic target whose efficacy has been demonstrated in several cancers. This study was conducted to evaluate the prognostic significance of PD-L1 expression in a large cohort of Middle Eastern PTC patie